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Introduction
Alternative RNA processing is determined by RNA-binding splic-
ing factors to generate different mRNA isoforms in a tissue-specif-
ic and developmental-regulated manner (1). Alterations in splicing 
factors or mutations in their target sequences result in misspliced 
gene products, which is the underlying cause of several human ge-
netic diseases (2–4).
RBM20 encodes the RNA-binding motif protein 20 with 
highly conserved functional domains: an RNA-recognition mo-
tif 1 (RRM-1) and an arginine/serine-rich (RS-rich) region. These 
structural features are characteristic of a family of SR and SR- 
related RNA-binding proteins (RBP) that assemble in the spliceo-
some and orchestrate the splicing of pre-mRNA. RBM20 is pre-
dominantly expressed in striated muscle, with the highest levels 
in the heart (5). Recently, mutations in RBM20 have been shown 
to cause human dilated cardiomyopathy (DCM) (6, 7), a major 
cause of heart failure and significant source of mortality and mor-
bidity worldwide (8). Given the role of RBM20 in cardiomyopa-
thy, efforts toward the identification of its RNA targets have been 
employed (5, 9) with the goal that their discovery would shed light 
upon human heart failure mechanisms and provide options for 
molecular therapy. No precise RNA recognition element (RRE) 
has been defined for RBM20, and with titin (Ttn), only a single 
bona fide mRNA target has been confirmed (5, 7). No protein in-
teraction partners have been identified for RBM20, despite the 
fact that previously reported RBM20 mutations associated with 
cardiomyopathy cluster in the RS-rich region (7) that is predicted 
to mediate protein-protein interactions (7, 10–12).
Here, we reveal the previously elusive RBM20 RRE at nucleo-
tide resolution using photoactivatable ribonucleoside–enhanced 
crosslinking and immunoprecipitation (PAR-CLIP) (13, 14) and 
transcriptome-wide RBM20-binding sites in heart-specific tran-
scripts using high-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation (HITS-CLIP) (15). To identify 
direct regulatory targets of RBM20, we integrated the crosslink-
ing immunoprecipitation (CLIP-seq) data with the analysis of 
transcriptomes of heart tissue obtained from WT rats and rats de-
ficient for RBM20 protein as well as human heart failure patients. 
These data yielded a transcriptome-wide RNA map for RBM20-
dependent splicing regulation in cardiac tissue. Using quantita-
tive SILAC-based proteomics (where SILAC indicates stable iso-
tope labeling by amino acids in cell culture) (16), we discovered 
RBM20 protein-binding partners. We revealed that RBM20 recog-
nizes splicing silencers at defined intronic positions and interacts 
with components of the spliceosomal complex A but not complex 
B. Importantly, patients with severe heart failure and low levels 
of RBM20 gene expression in heart tissue show a loss of splicing 
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mapped to the human genome with up to 1 mismatch. A hallmark 
of PAR-CLIP is the occurrence of diagnostic nucleotide transitions 
of crosslinked thio-nucleosides during reverse transcription. The 
PAR-CLIP reads aligned with T to C mismatches in 4SU, and G to A 
in 6SG libraries, respectively, indicating specific mRNA-RBM20 
crosslinking (Supplemental Figure 1C). To investigate only those 
binding sites that were supported by reads from at least 2 out of 
3 experiments, we computationally analyzed all 3 libraries jointly 
(see Methods; ref. 14) with an estimated false discovery rate (FDR) 
below 5% (Supplemental Figure 1, D and E). Within target tran-
scripts (Supplemental Table 2), the resulting consensus read clus-
ters mapped most frequently to introns (Figure 1A).
Identification of the RBM20 RRE. The diagnostic nucleotide 
transitions of PAR-CLIP experiments have been shown to occur 
at crosslinking sites and reflect the immediate positions of cellu-
lar RBP-RNA interactions (13). To elucidate the sequence prefer-
ence of RBM20, we performed 5-mer counting in crosslink-cen-
tered regions (CCRs) derived from 4SU and 6SG experiments. 
The most abundant element was the UCUUA 5-mer, followed by 
variations of this element, all containing a UCUU core (Figure 1B). 
These UCUU-containing 5-mers were most strongly enriched 
not only in the 4SU but also in the 6SG experiment, demonstrat-
repression for several previously unknown direct RBM20 targets 
compared with those of high RBM20-expressing patients. Endog-
enous differences of RBM20 expression may thus modulate car-
diac function and may contribute to the molecular events respon-
sible for cardiomyopathy and heart failure.
Results
Transcriptome-wide identification of RBM20-binding sites. To 
identify cis-acting RNA elements recognized by RBM20, we per-
formed PAR-CLIP in human embryonic kidney 293 (HEK293) 
cells with stable, inducible expression of N-terminally FLAG/HA-
tagged human WT RBM20. The epitope-tagged RBM20 localized 
predominantly to the nucleus, consistent with a role in splicing, 
with no detectable endogenous RBM20 expression (Supplemental 
Figure 1A; supplemental material available online with this article; 
doi:10.1172/JCI74523DS1). PAR-CLIP experiments were carried 
out independently with 4-thiouridine (4SU) and 6-thioguanosine 
(6SG) to reduce bias for specific nucleotide compositions (Supple-
mental Figure 1B). Crosslinked RNA of 2 4SU and 1 6SG experi-
ment was recovered, transcribed into cDNA libraries, and Illumi-
na sequenced. For each library, we generated more than 2 million 
distinct sequencing reads (Supplemental Table 1) that uniquely 
Figure 1.
PAR-CLIP in HEK293 cells identifies RBM20 RRE. (A) Transcriptome-wide distribution of RBM20 PAR-CLIP consensus library clusters. The ratio of 
PAR-CLIP to control HEK293 RNA-seq percentage coverage in each region is displayed. (B) Binding motif enrichment in RBM20 PAR-CLIP libraries. The 
log2 enrichments of 5-mers in cluster-centered regions of the 4SU and 6SG libraries are correlated. UCUU core–containing 5-mers were most abundant. 
(C) Sequence logo for the RBM20 RRE was computed from the top 1000 intronic binding sites of the consensus library using MEME. (D) Positional 
transition frequency for intronic PAR-CLIP clusters anchored at the UCUU core of the RBM20 RRE (black line) and control CCRs randomly placed in 
the same intron (blue line). (E) Phosphorimage of native PAGE resolving complexes of immunoprecipitated full-length RBM20 protein with WT and 
mutated Ryr2 target RNA oligonucleotides.
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and 6SG residues as expected (13). We performed EMSA using 
immunoprecipitated full-length epitope-tagged RBM20 to show 
that RBM20 binds an intronic RRE in the ryanodine receptor 2 
(Ryr2) transcript (Figure 1E), validating the motif prediction. We 
compared different degrees of UCUU core mutations in Ryr2. We 
found that not only mutation of the entire core but also mutation 
of 2 core nucleotides led to a complete inhibition of RBM20 bind-
ing (Figure 1E), while a single nucleotide change within the core 
already led to a marked reduction in RBM20-RNA interaction 
(Supplemental Figure 2C).
Analysis of natural selection in RBM20-binding sites. To corrob-
orate the functional significance of the RBM20 RRE in humans, 
we analyzed population genetics data for signatures of negative 
selection (17). Using SNP data from the 1000 Genomes Project 
(http://www.1000genomes.org/), we first analyzed the density of 
SNPs in RBM20 RREs or CLIP clusters in HEK293 cells. We found 
a significant decrease of SNPs/kb in clusters compared with in-
trons and exons, with a further decrease in RREs compared with 
clusters in all 4 populations of the 1000 Genomes Project (Supple-
mental Figure 1D). Since this result might be affected by heteroge-
neity of mutation rates, we compared the distributions of derived 
ing that the enrichment of the uridine-rich motif is supported by 
independent labeling experiments. We also performed 6-mer 
and 7-mer counting in CCRs derived from separate 4SU and 6SG 
experiments and the consensus library. Overall there was a sig-
nificantly correlation between the 3 individual libraries for the 
UCUU core–containing 6- (Supplemental Figure 2A) and 7-mers 
(data not shown). In each of the libraries, the UCUU core–con-
taining elements were strongly enriched compared with a set of 
control sequences with similar nucleotide content (Supplemen-
tal Figure 2B). The sequence logos for the RRE computed from 
the 1000 intronic CCRs with the highest number of character-
istic nucleotide conversions in the consensus library showed 
that enriched n-mer sequences all contained a UCUU core and 
only varied in flanking nucleotides (Figure 1C). We analyzed the 
probability of nucleotide transitions in UCUU-containing clus-
tered sequence reads of the consensus library. This showed that 
thionucleosides within the element were frequently altered, with 
the first and second U showing the highest transition frequen-
cy, supporting the validity of the identified motif (Figure 1D). 
Moreover, we observed an increased T-to-C conversion frequency 
in the 15 nucleotides flanking the motif due to crosslinking of 4SU 
Figure 2. HITS-CLIP in rat cardiomyocytes. (A) Transcriptome-wide distribution of HITS-CLIP–derived RBM20 target sites in cardiomyocytes. The ratio of 
HITS-CLIP to cardiac RNA-seq percentage coverage in each region is displayed. (B) Binding motif enrichment in cardiomyocyte Rbm20 clusters. The log10 
frequencies of 5-mers in clusters correlated with frequencies of 5-mers in control sequence. (C) Sequence logo for the RBM20 RRE in cardiomyocytes was 
computed from the top 1000 intronic binding sites using MEME. (D) Confirmation of alternative splicing of genes with high ΔPSI values as determined by 
RNA-seq. i1 indicates isoforms expressed at higher levels in WT than in mutant rats and i2 those expressed at higher levels in mutant than in WT rats. 
Rbm20 was amplified as control and verifies the indicated Rbm20 genotype of the samples tested. (E) ΔPSI values > |0.01| of RBM20-regulated exons in 
WT versus Rbm20-deficient rat hearts. RBM20 acts predominantly as a splicing repressor in cardiomyocytes. (F) RBM20-regulated versus expected cardiac 
splicing events. MXE, mutually exclusive exon; CE, cassette exon; CNE, constitutive exon.
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by RT-PCR and quantitative PCR (qPCR) (Figure 2D 
and Supplemental Figure 3, A and B). To distinguish 
direct RBM20-associated splicing events from those 
that may be secondary in nature, we intersected the 
list of transcripts containing differentially spliced 
exons with HITS-CLIP–derived RBM20-binding 
sites (Supplemental Figure 3B). This identified 97 
RBM20-regulated exons (Supplemental Table 5), 
of which 80 (82%) were located in 18 genes that 
carried RBM20 HITS-CLIP clusters (Table 1). Of 
the RBM20-regulated exons, 4 times more were re-
pressed than activated, suggesting a role of RBM20 
as a splicing repressor in the heart (Figure 2E). We 
found that mutually exclusive splicing was the most 
significantly enriched RBM20-regulated splicing 
event, which we observed approximately 14-fold 
more often than expected in cardiac-expressed 
transcripts (P = 1.55 × 10–11) (Figure 2F). Mutually 
exclusive splicing is frequently involved in regulat-
ing highly tissue-specific functions (19) and is in line 
with the specific expression pattern of RBM20.
Intronic RBM20-binding positions flanking al-
ternative exons correlate significantly with splicing 
repression. In Ttn, the identified RBM20-binding 
sites were predominantly located in the PEVK- and 
the immunoglobulin-rich regions within the I-band and were as-
sociated with aberrant splicing of consecutive exons in these re-
gions (Figure 3A). RBM20-binding sites in the direct targets LIM 
domain binding 3 (Ldb3) and calcium/calmodulin-dependent 
protein kinase II δ (Camk2d) were closely located near mutually 
exclusive spliced exons (Figure 3, B and C). This led us to deter-
mine whether the position of RBM20-binding sites on pre-mRNA 
is indicative for the occurrence of differential exon usage. We 
found a significant overrepresentation of RBM20-binding sites in 
a window spanning 400 bp upstream of the 5′ splice site to 400 bp 
downstream of the 3′ splice site of differentially spliced exons 
(Odds ratio = 78.99, P < 2.2 × 10–16). In transcripts with both dif-
ferential exon usage and RBM20-binding sites, 97% of clusters 
contained the identified RRE (UCUU), indicating its functional 
significance. We further differentiated between RBM20-activated 
and -repressed events and computed the mean CLIP-read density 
within or near regulated and control exons on a global and high-
resolution scale. Very little RBM20 binding was associated with 
exon activation (Figure 3D). In contrast, RBM20 binding peaked 
50 nucleotides upstream and 100 nucleotides downstream of re-
pressed exons. This indicates that RBM20 binding predominantly 
at these distinct positions is required for exon repression.
We used a reporter assay to determine whether the identi-
fied cardiac RBM20-binding positions are necessary for splicing 
activity. The splice reporter construct was based on the RBM20-
dependent N-terminal titin PEVK region with a firefly luciferase 
in the alternative exon 8 (PEVK8), a cluster containing 2 UCUU 
RREs approximately 100 bp downstream of exon 8, and a Renilla 
luciferase in the 3′ exon (Figure 3E and Supplemental Figure 3D). 
Mutation of the UCUU elements within the cluster sequence re-
sulted in the reduced exclusion of PEVK8 (Figure 3E). On the other 
hand, nucleotide changes in UCUU sequences without evidence 
allele frequencies (DAFs) of SNPs in RREs and clusters to intronic 
and exonic SNPs and observed an enrichment of small DAFs in 
motifs and clusters when located in introns (Supplemental Figure 
1E). Testing whether the DAF distributions differ among groups 
confirmed that DAF distributions are shifted significantly toward 
smaller values (Supplemental Table 3).
HITS-CLIP in rat cardiomyocytes reveals direct heart-specific 
targets. Cardiomyocytes are terminally differentiated cells with 
highly specialized functions. Although the majority of the tran-
scriptome from HEK cells is also expressed in cardiomyocytes, 
expression profiles differ substantially among these cell types, 
with several transcripts that are specific to the cardiac muscle. To 
detect heart-specific RBM20-binding sites, we crosslinked en-
dogenous RBM20 protein with pre-mRNA in rat cardiomyocytes 
and performed high-throughput sequencing of immunoprecipi-
tated RNA (HITS-CLIP) (15). The HITS-CLIP libraries were ana-
lyzed essentially with the same computational approaches as for 
the PAR-CLIP experiments (see Methods). The most prominent 
RBM20-bound target RNA in cardiomyocytes was Ttn (Supple-
mental Table 4), the only direct RBM20 target previously known 
(5, 9). Transcriptome-wide, cardiac RBM20 clusters mapped pre-
dominantly to introns, as observed in HEK293 cells (Figure 2A). 
Our motif analysis of the HITS-CLIP data identified the same RRE 
in cardiomyocytes and mirrored our findings from the PAR-CLIP 
experiments (Figure 2, B and C).
RBM20 represses cassette and regulates mutually exclusive exon 
splicing. To detect RBM20-dependent exon usage in the heart, we 
analyzed existing paired-end sequencing data of RNA from Rbm20–/– 
and WT rat hearts using DEXSeq (18). We quantified changes in 
alternative splicing by comparison of percentage spliced in (PSI) 
values, representing the fraction of mRNAs that include an alterna-
tive exon (Supplemental Table 5), and validated several candidates 
Table 1. Direct RBM20-regulated genes
Gene ID Gene symbol Name
ENSRNOG00000011589 Camk2d Calcium/calmodulin-dependent protein kinase II delta
ENSRNOG00000012207 Dst Dystonin
ENSRNOG00000031934 Enah Enabled homolog (Drosophila)
ENSRNOG00000009097 Immt Inner membrane protein, mitochondrial
ENSRNOG00000011343 Ldb3 LIM domain binding 3
ENSRNOG00000009702 Lmo7 LIM domain only protein 7
ENSRNOG00000005934 Mlip Muscular-enriched A-type laminin-interacting protein
ENSRNOG00000019892 Lrrfip1 Leucine-rich repeat (in FLII) interacting protein 1
ENSRNOG00000016983 Myh7 Myosin heavy chain 7
ENSRNOG00000026700 Myom1 Myomesin 1
ENSRNOG00000012512 Nexn Nexilin
ENSRNOG00000022790 Obscn Obscurin
ENSRNOG00000012658 Pdlim3 PDZ and LIM domain 3
ENSRNOG00000004621 Rtn4 Reticulon 4
ENSRNOG00000017060 Ryr2 Ryanodine receptor 2
ENSRNOG00000015658 Sorbs1 Sorbin and SH3 domain containing 1
ENSRNOG00000033734 Tnnt2 Troponin T type 2
ENSRNOG00000022637 Ttn Titin
The listed direct targets show Rbm20-dependent differential splicing and are directly bound 
by RBM20.
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with 138 proteins being frequently identified in multiple spliceo-
some preparations (20). In particular, we found all 7 Sm and nearly 
all U1 and U2 small nuclear ribonucleic particle (snRNP) proteins 
(except SNRPA, SNRPB2, SF3B5, and PHF5A) to precipitate with 
RBM20 (Figure 4C). In contrast, only few of the U4/U6 and U5 
snRNP proteins were identified in the RBM20 pull-down. In addition, 
while we identified 45% of complex A–specific proteins, including 
U2AF65 and U2AF35, we found only 18% and 11% of complex B– or 
complex C–specific proteins, respectively (Supplemental Figure 4). 
In particular, only 3 out of 20 proteins of the Prp19 complex and 
related proteins that are crucial during catalytic activation and join 
the spliceosome during complex B formation were found. Together, 
these data suggest that RBM20 interacts with U1 and U2 in early 
stages of spliceosome assembly, while it is not present in catalyti-
cally active complexes. It has been shown that the RS-rich region of 
for RBM20 binding did not affect reporter activity. This is further 
supported by mobility shift assays, in which we document that 
RNA containing the cluster-binding site downstream of PEVK8 
interacted with the RRM domain of RBM20 (RNA I), while RNA 
containing UCUU elements that do not correspond to the cluster 
(RNA II and III) did not bind to RBM20 (Figure 3E).
Mutation of the RBM20 RS–rich region abrogates protein-protein 
interactions with other splicing factors. To identify RBM20 interaction 
partners, we used quantitative affinity purification followed by mass 
spectrometry (q-AP-MS) in SILAC-labeled HEK293 cells (ref. 16  
and Figure 4A). In total, we identified 538 proteins precipitating with 
RBM20 (2-fold enriched compared with controls) and validated sev-
eral interactions by Western blotting (Figure 4B and Supplemental 
Table 6). This set of proteins was significantly enriched for the Gene 
Ontology (GO) Biological Process “RNA splicing” (P = 2.7 × 10–38) 
Figure 3. RBM20 binds to intronic splicing silencers upstream and downstream of repressed exons. (A–C) ΔPSIs are shown as black lines (WT compared 
with homozygous rats). Elevated versus decreased ΔPSIs show inclusion or exclusion of exons, respectively. Red ticks indicate mapped RBM20 cluster 
positions. (A) Ttn is predominantly spliced in the elastic region. Mapped RBM20-binding sites coincide with differential splicing. (B) Camk2d exons 14–16 
are mutually exclusive and regulated by RBM20. Mapped RBM20-binding sites are located upstream of exon 14 and downstream of exon 15. (C) Ldb3 
undergoes an exon switch affecting exon 4 versus exons 5–7. Mapped binding sites are upstream of exon 5 and downstream of exon 8. (D) Mean CLIP 
density near RBM20 activated (red) and repressed exons (blue). Dotted line indicates density around exons not regulated by RBM20. Gray shows 90% CIs. 
(E) Right panel: specific activity of RBM20 on Ttn RNA from the PEVK region in a splice-reporter assay. Rbm20 expression leads to exclusion of the firefly 
luciferase–containing (Fluc) exon. Ratio of Fluc to Renilla luciferase (Rluc) activity (downstream exon) reflects splice activity. Reporter activity depends 
on mutation of 2 UCUU elements in cluster CID016226, but not outside the cluster. Mutations are indicated as X. White boxes only show native reporter. 
Controls: PEVK-construct cotransfected with empty vector (–), Rbm20 cotransfected with a Ttn M-band region construct not affected by RBM20 (M).  
***P < 0.001 compared with native reporter. Left: EMSA evaluating RBM20 binding to Ttn PEVK-derived RNAs. White arrows indicate input RNA; black 
arrows indicate RNA-protein complex.
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RBM20 is a hot spot for mutations that cause DCM. We therefore 
determined the impact of a previously reported RBM20 S635A mu-
tation located in the RS-rich region (5) on protein binding by compar-
ing proteins precipitating with WT RBM20 versus S635A-RBM20. 
The mutation did not abrogate interactions with core spliceosomal 
proteins, but for 38 of the alternative spliceosomal proteins asso-
ciated with WT RBM20, interactions were significantly reduced 
when the RS-rich region of RBM20 was mutated (Figure 5A). To 
distinguish RNase insensitive interactions indicating binders not de-
pendent on RNA as a connector, we repeated the experiment with 
an RNase digestion step after immunoprecipitation and compared 
the results with the nondigested data set. This revealed 13 of the 
WT-specific spliceosomal protein interactions as RNase insensitive 
(Figure 5B). Using a label-free quantification, 10 of these RNase 
insensitive WT-specific proteins identified in HEK cells were also 
found to precipitate with endogenous-expressed RBM20 in cardio-
myocytes (Figure 5B). Overall, the set of interaction partners in car-
diomyocytes encompassed the majority of splicing factors identified 
in the SILAC experiment, including U2AF65 and U2AF35, but only 1 
protein of the Prp19 complex (Supplemental Table 7), corroborating 
our findings from HEK cells in cardiomyocytes.
Regulatory impact of RBM20 on cardiomyopathy-associated 
and novel candidate genes. NCBI Medical Subject Heading (MeSH) 
analyses of all 18 directly RBM20-regulated targets revealed that 
the set was significantly enriched for the heading “dilated car-
diomyopathy” (P = 1.33 × 10–13) (Supplemental Table 8). Further 
significantly enriched disease-related MeSH terms were “hy-
pertrophic cardiomyopathy” (P = 1.8 × 10–09) and “heart failure” 
(P = 8.48 × 10–05). The identification of direct RBM20 target genes 
and their regulated exons allowed us to specifically test their rele-
vance in a large cohort of heart failure patients, including a single 
patient that we reported previously with a heterozygous S635A 
mutation in RBM20 (5).
We compared the rat cardiac-splicing patterns of direct tar-
gets to those of the RBM20 S635A individual and 5 control sub-
jects with DCM, but without any nonsynonymous changes in their 
RBM20-coding sequence (Supplemental Table 9). This analysis 
revealed conserved differential splicing of orthologous direct tar-
gets at the exon level for Camk2d, Ldb3, LIM domain only protein 
7 (Lmo7), PDZ and LIM domain 3 (Pdlim3), reticulon 4 (Rtn4), 
Ryr2, and Ttn (Figure 6 and Supplemental Figure 5). As expected 
from our analysis, the differentially spliced exons were flanked 
Figure 4. Identification of RBM20 protein-protein interaction partners. 
(A) q-AP-MS using SILAC. Differentially SILAC-labeled HEK293 cells (light, 
medium, and heavy) were transfected with FLAG-tagged control vector, 
FLAG-tagged RBM20 WT, or S635A mutant. RBM20 protein complexes 
were enriched by affinity purification and analyzed by quantitative mass 
spectrometry. (B) The log2 ratios of protein-protein interactions for WT-
RBM20 versus control are shown on the left. Red dots indicate known 
splicing factors. Validation of q-AP-MS hits by Western blotting is shown 
on the right. (C) U1–, U2–, and U4/U6.U5–specific proteins are grouped 
according to snRNP association and highlighted in blue when identified as 
interacting with RBM20.
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Figure 5. Impact of RBM20 S635A mutation on protein-protein interaction. (A) WT versus S635A comparison. RBM20 was identified as highly and 
equally abundant in WT- and S635A-RBM20 samples, indicating successful immunoprecipitation. Red circles indicate spliceosomal interaction part-
ners not affected by the mutation. Labeled red dots indicate spliceosomal interaction partners specific to WT- (log2 ratio > 0.4) or S635A-RBM20 (log2 
ratio < –0.4). (B) Comparison of RNase-digested versus nondigested q-AP-MS identifies RNase-insensitive RBM20 interactors. Upper right quadrant 
contains WT- and lower left quadrant mutant-specific interactors enriched in RNase-digested and nondigested samples. Spliceosomal interaction 
partners are marked by red dots and labeled when WT- or mutant-specific in both protein-protein interaction screens. Bold labeled proteins were iden-
tified as also interacting with RBM20 in cardiomyocytes.
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patients with end-stage heart failure, we observed that cardiac 
RBM20 expression greatly varies among individuals (Supplemen-
tal Figure 6). We compared the splicing patterns of RBM20-reg-
ulated exons in 10 individuals, each with the highest versus low-
est RBM20 expression (Figure 7 and Supplemental Table 9). The 
difference in endogenous RBM20 expression (high vs. low) sig-
nificantly affected the splicing of orthologous exons for CAMK2d, 
LDB3, RYR2, and TTN and mirrors our observations from the 
S635A mutant patient and Rbm20-deficient rats. Given the fun-
damental role of these targets for proper heart function, this may 
suggest that endogenous RBM20 expression levels are important 
for the modulation of cardiac function.
by RBM20 clusters in downstream and/or upstream introns in all 
cases. In addition to Ttn, Ldb3 and Camk2d have previously been 
suggested as RBM20 regulated. Here, we confirm that the direct 
interaction between RBM20 and their pre-mRNA leads to the ob-
served differential exon usage in rats and humans (Supplemental 
Figure 5). Interestingly, Lmo7, Pdlim3, Rtn4, and Ryr2 have not 
been implicated in the molecular target framework of RBM20 so 
far, but are here clearly identified as RBM20 regulated (Figure 6 
and Supplemental Figure 3B).
Moreover, we tested the impact of differential expression 
levels of RBM20 on the splicing of its target exons in cardiac tis-
sue from a human heart-failure cohort. In heart tissue from 148 
Figure 6. Alignment of orthologous rat and human exons for Ryr2, Lmo7, Rtn4, and Pdlim3 to compare RBM20-regulated exon usage. PSI scores for the 
RBM20-deficient individual (S635A) are indicated in red and the average of 5 control subjects from the human heart failure cohort (CP) in blue. The aver-
age PSI of 3 rats per genotype is shown below (WT in blue and Rbm20–/– in red). Resulting ΔPSIs are shown in black (S635A compared with CP) and in gray 
(WT compared with Rbm20–/– rats). Deflections in ΔPSI values in differentially spliced regions are highly conserved across species. (A) Ryr2 shows RBM20-
dependent splicing of a 24-bp exon included in RBM20-deficient hearts. The magnified view shows RBM20 cluster flanking the differentially spliced rat 
Ryr2 exon. (B) In Lmo7, RBM20 deficiency causes retention of exons 9 and 10. The zoom-in shows RBM20 cluster flanking exon 10 immediately upstream 
of its 3′ splice site. (C) Rtn4 exons 3 and 4 are differentially spliced. The magnification shows the intronic RBM20 cluster flanking rat exons 3 and 4. (D) 
Pdlim3 exons 4–6 are mutually exclusive and differentially regulated by RBM20. The zoom-in shows the locations of RBM20 cluster upstream of exon 4.
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nantly to introns near the 3′ and 5′ splice 
sites of repressed exons and in close proxim-
ity to the binding sites of U1 and U2 snRNPs. 
The binding of RBM20 to RNA appears to be 
important, as mutating the RBM20-binding 
site affects the splicing activity. Further-
more, mice lacking the RBM20 RNA recog-
nition motif-1 domain (inframe deletion of 
exons 6 and 7) show aberrant splicing of its 
major target, Ttn (26).
We demonstrated the interaction of 
RBM20 with nearly all U1 and U2 snRNP 
proteins as well as U2-related proteins (in-
cluding U2AF65 and U2AF35) by quantita-
tive proteomic approaches. The data sug-
gested a predominant presence of RBM20 
in complex A, but not in catalytically ac-
tive spliceosomes. This was supported by 
interactions of RBM20 with spliceosomal 
proteins that are exclusively represented in 
complex A but missing with complex B pro-
teins such as the U4/U6.U5 tri-snRNP and 
the Prp19 complex. We speculate that the 
particular RBM20-binding sites may prevent 
the recruitment of the U4/U6.U5 tri-snRNP 
interfering with complex B formation subse-
quently leading to splicing repression.
Interaction with other proteins is pre-
dicted to be mediated by the SR-rich re-
gion of RBM20 (7). Here, we showed that a 
disease-causing mutation underlying DCM 
within the SR-rich region disrupted the in-
teraction of RBM20 with alternative splicing 
factors, but did not interfere with core splic-
ing factor binding. This suggests that RBM20 presence in complex 
A may need to be stabilized by additional alternative splicing fac-
tors. Disruption of this process may lead to subsequent displace-
ment from the spliceosome and loss of splicing repression, as ob-
served in Rbm20 deficiency.
The combination of the splicing analysis and determination 
of direct RNA-binding sites in the heart revealed several directly 
regulated RBM20 targets unknown to date. We discovered DCM-
related and several other genes implicated in cardiac disorders 
and validated representatives in human heart failure patients. 
Interestingly, the identified targets allow further insights and re-
veal new RBM20-related disease mechanisms: RYR2 is found 
primarily in cardiac muscle and is a component of the major Ca2+ 
release channel for excitation-contraction coupling in the sarco-
plasmic reticulum membrane. A 24-bp exon in RYR2 is upregulat-
ed in Rbm20-deficient rats and human cardiomyopathy patients 
(Figure 6A). This exon is usually present at low levels in hearts and 
shifts RYR2 from the ER to the intranuclear Golgi apparatus, with 
profound effects on intracellular Ca2+ signaling (27). Mutations in 
N-terminal domains of RYR2 have been associated with arrhyth-
mogenic right ventricular tachycardia and sudden death (28). 
Cardiac arrhythmia and sudden death are both signs of RBM20-
related DCM (5), and recent studies suggest that defective RYR2 
Discussion
In the current study, we identified direct cardiac targets of RBM20 
and revealed its immediate binding sites in these transcripts. We 
showed that RBM20 binds to a UCUU-containing RNA element 
in nascent transcripts in rat as well as human cells, indicating the 
conservation of the binding site and splicing regulation across 
species. We found evidence for negative selection on RBM20-
binding sites in human populations. RREs and CLIP clusters 
were significantly depleted of SNPs, and SNPs occurring inside 
motifs or clusters were enriched for small DAFs. These findings 
underscore the functional significance of RBM20-binding sites 
in humans, as variants in binding sites are evolutionary selected 
against throughout the genome.
Importantly, we found that RBM20 predominantly binds to 
intronic sequence in close proximity to differentially spliced ex-
ons. SR and SR-related proteins are usually regarded as splicing 
activators (10), recognizing exonic splicing enhancers (21). Inter-
estingly, there are sporadic examples of SR protein involvement 
in splicing repression. For few targets, it has been recently shown 
that this protein family can repress splicing when bound at intron-
ic positions (22–25), but SR and SR-related proteins have not yet 
been shown to act transcriptome wide as splicing repressors from 
intronic positions. Here, we found that RBM20 binds predomi-
Figure 7. Splicing patterns of RBM20-regulated exons in individuals with differential endog-
enous RBM20 expression levels. ΔPSI values for RBM20 regulated exons of (A) TTN, (B) RYR2, (C) 
CAMK2D, and (D) LDB3 are shown in red for low compared with high RBM20-expressing individuals. 
ΔPSI values for S635A compared with control subjects shown in gray serve as indicators of RBM20 
regulated events.
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In our study, we describe the function of RBM20 as a molecu-
lar switch that orchestrates isoform transitions of a network of 
genes with essential cardiac functions. Not only genetic variation, 
but also the modulation of RBM20 gene expression levels, is op-
erative in the regulation of this network of direct targets in the hu-
man heart. This is of interest because the modulation of RBM20 
levels may be an attractive target for therapeutic intervention. 
Moreover, the abundance of RBM20 in heart tissue could play a 
role in the pathogenesis of more common forms of heart failure 
irrespective of the RBM20 genotype. The clinical significance of 
splicing controlled by RBM20 expression levels during the patho-
genesis of common forms of heart failure will be an interesting av-
enue to explore in future studies.
In summary, our analyses tie together RBM20-regulated di-
rect targets, the underlying mechanism of splicing repression, 
and molecular consequences in clinical samples. Collectively this 
provides insights that are extensible into the pathophysiology of 
human cardiac function.
Methods
PAR-CLIP. HEK293 cells with tetracycline-inducible expression of 
FLAG/HA-tagged RBM20 have been described previously (5). For 
PAR-CLIP, we essentially followed the protocol previously described 
(13). The libraries were sequenced on an Illumina Genome Analyzer 
GAII using the 50-bp single-read protocol.
HITS-CLIP. Neonatal rat ventricular myocytes (NRVMs) were 
isolated from SD rats using a modification of the Kasten’s technique, 
as described (38). At 48 hours after isolation, cardiomyocytes were 
irradiated 1 time at 400 mJ/cm and an additional 200 mJ/cm with 
254 nm UV light and lysed in NP40 lysis buffer. After DNAse and 
RNase T1 treatment, the lysate was immunoprecipitated using 
RBM20 antibody (5) covalently coupled to Protein G Dynabeads 
(Invitrogen). Radiolabeling of immunoprecipitated RNA, protein-
RNA complex separation, sequencing library preparation, and 
sequencing were done following the PAR-CLIP protocol.
Computational analysis of PAR-CLIP and HITS-CLIP data. We 
used a computational pipeline that performed all steps of the analysis 
from raw reads to cluster sets and target genes, essentially as previ-
ously described (14), with emphasis on stringent filtering and con-
trolling the false-positive rate in the identification of binding sites 
(Supplemental Methods).
Motif analysis. Word counting was performed on CCRs for PAR-
CLIP and complete read clusters for HITS-CLIP. The log2 word enrich-
ment was computed for intronic-binding sites as the log ratio of the 
relative frequency of each 5-mer to the background frequency in Ref-
Seq introns. Words with less than 10 occurrences inside binding sites 
were discarded from the analysis.
Within PAR-CLIP CCRs, we searched for the UCUU that was clos-
est to the anchor position and selected it as the new center. CCRs with-
out UCUU were discarded. The remaining motif-centered regions 
(MCRs) were used to build an average profile of nucleotide conversion 
events, indicative of crosslinking, around the motif.
Human studies. We obtained cardiac tissue from 147 subjects with 
end-stage heart failure. All subjects were transplanted at the Royal Bromp-
ton and Harefield NHS Foundation Trust (London, United Kingdom). 
On this occasion, cardiac samples were obtained and immediately fro-
zen in liquid nitrogen. The S635A patient was described earlier (5).
function may be associated not only with cardiac arrhythmias, but 
also cardiomyopathies (29, 30). Here, we were able to show that 
the 24-bp exon is also regulated in human heart failure patients 
with high and low RBM20 expression.
LMO7 is a transcription factor that previously has not been as-
sociated with DCM. In LMO7, RBM20 deficiency resulted in re-
tention of exons 9 and 10 across species (Figure 6B). These exons 
encode an F-box domain present only in a brain-specific isoform 
of LMO7 (31). Its function in regulating expression of genes that 
are important for skeletal muscle and heart function (32) makes it 
an interesting modulator in RBM20-related DCM.
RTN4 protein, also known as neurite outgrowth inhibitor 
(NOGO), localizes predominantly in the endoplasmic reticulum. 
It is well studied in the nervous system, but its function in the 
heart remains largely unknown. In RBM20-mutant rats and hu-
man, exons 3 and 4 of RTN4 are retained (Figure 6C). This iso-
form is most strongly expressed in the brain and only weakly in 
the heart (33). It is increased in left ventricular tissue from DCM 
and ischemic hearts and has been proposed as a potential indica-
tor of heart failure (34–36). Here, we demonstrate that RBM20 
represses the predominantly neuronal isoform in favor of the 
heart-specific exon usage.
PDLIM3 binds α-actinin 2 in the Z-discs of myofibers. Two 
different major isoforms of PDLIM3 are expressed in heart and 
skeletal muscle tissue that include either exon 4 or exons 5 and 
6. The predominant isoform in the heart includes exon 4 (37). In 
RBM20-deficient rats and human, the ratio of these 2 isoforms is 
shifted toward the skeletal muscle form (Figure 6D). Within exon 
4, a Glu106Ala mutation has been linked to hypertrophic cardio-
myopathy, indicating the importance of the sequence encoded by 
this exon for proper heart functioning (37).
Considering the fundamental role of RBM20 for proper splic-
ing of cardiac transcripts, it was unexpected that its endogenous 
expression levels in heart failure patients varied drastically. On 
the other hand, this could also be an indication that differences in 
RBM20 expression levels contribute to the modulation of cardiac 
function under pathophysiological conditions. With the set of di-
rect RBM20 target genes defined in this study, it was possible to 
investigate the impact of RBM20 expression on differential exon 
usage in its targets in cardiac tissue from end-stage heart failure 
patients. Despite the heterogenous nature of the human heart fail-
ure samples, we could demonstrate the regulation of differential 
exon usage in 4 direct RBM20 target genes in 10 patients with 
high versus 10 patients with low RBM20 gene expression levels 
(CAMK2D, LDB3, RYR2, TTN). These 4 genes showed the stron-
gest differences in RBM20-regulated exon usage across species. 
It is therefore conceivable that we have missed other targets with 
smaller effects in our analysis due to the heterogeneous nature 
of the patient samples. The validity of our findings, on the other 
hand, is supported by the fact that the same exons within the 4 
genes were also regulated in a patient that carried an RBM20 non-
synonymous mutation (S635A) in the SR-rich region. Given the 
suggested impact of RBM20 expression levels on exon usage of its 
direct targets, we paid careful attention to comparing the S635A 
patient to human cardiomyopathy controls that were matched in 
their expression levels but did not have any nonsynonymous vari-
ants in their RBM20-coding sequence.
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amplitude. Several mutations were introduced into the reporter con-
struct, as described in Supplemental Methods. HEK293 cells (25000 
cells/well on 96-well plates) were transfected with the reporter-plas-
mids and CMV-driven RBM20 or control plasmid (pcDNA3.1) using 
Polyethylenimine 40 kDa (Polysciences Europe GmbH). At 72 hours 
after transfection, reporter activity was measured using the Dual-
Luciferase Reporter Assay System (Promega), following the manufac-
turer’s instructions, and an infinite M200 Pro Plate Reader (TECAN). 
Ratios of firefly to Renilla luciferase activity were normalized to the 
RBM20-negative control. Results were confirmed in 3 independent 
experiments. Based on the half-life of the resulting protein, we found 
higher sensitivity of the RNA-based splice analysis as compared with 
the luciferase readout (Supplemental Figure 3, E and F).
SILAC experiments. SILAC labeling of HEK293T cells, immunopre-
cipitation, and LC-MS/MS analysis were essentially performed as previ-
ously described (16) (for details see Supplemental Methods). Label swap 
experiments were performed to filter out contaminants. Experiments 
were performed in quadruplicate. Biological replicates were grouped 
and enriched proteins determined by 1-sample t test (ratio cut off: 1.3).
Accession numbers. PAR-CLIP, HITS-CLIP, HEK transcriptome, 
and human cardiac transcriptome sequencing data are available at the 
Sequencing Archive of the European Nucleotide Archive (ERP001301 
and E-MTAB-2572).
Statistics. Data are presented as mean ± SD unless otherwise indi-
cated. Differences between experimental groups were analyzed by 
2-tailed Student’s t test unless otherwise specified. P < 0.05 was con-
sidered statistically significant.
Study approval. All human studies were approved by the institution-
al review board of the Cardiovascular Biomedical Research Unit, Royal 
Brompton and Harefield NHS Trust, and individuals gave informed 
consent. All experiments involving animals were performed in accor-
dance with institutional and NIH guidelines and approved by the 
Landesamtes für Gesundheit und Soziales (LaGeSo), Berlin, Germany.
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RNA-seq and splicing analyses. Total RNA was extracted using TRIzol 
reagent and RNA-seq libraries prepared with the TruSeq RNA Sample 
Preparation Kit (Illumina). Barcoded cDNA fragments of poly(A)+ RNA 
were then sequenced on a HiSeq 2000 instrument from Illumina with 
2 × 100 bp PE chemistry. Reads were mapped against the reference 
genome GRCh37 using TopHat version 1.3.1 (39) supplied with the gene 
annotation of the Ensembl database (40). We used DEXSeq (18) to test 
all exons for differential usage and to reanalyze previously published 
RNA-seq data of Rbm20-deficient rats (Sequencing Archive of the 
European Nucleotide Archive, http://www.ebi.ac.uk/ena/; accession 
code ERP001301), as detailed in Supplemental Methods.
Gene expression analysis in the heart failure cohort. Gene expression 
in the heart failure cohort individuals was measured using RNA-seq. 
For each protein coding gene from the NCBI annotation, version 66, 
the overlapping TopHat aligned reads were counted using the HTSeq 
package. Counts across samples were normalized using a quantile 
based scaling method (41). Gene expression levels were adjusted for 
available covariates as described in Supplemental Methods.
EMSA. For EMSA, FLAG/HA-tagged full-length RBM20 or GST-
tagged Rbm20 RRM domain was used (see Supplemental Meth-
ods). γ-32P–labeled RNA was incubated with immunoprecipitated 
RBM20 protein and 100 ng tRNA in 20 μl binding buffer (10 mM 
HEPES-KOH, pH 7.9, 50 mM KCl, 3 mM MgCl2, 1 mM DTT, and 5% 
glycerol). The resulting complexes were resolved on native 5% acryl-
amide gels run at 4°C at 200 V for 2 hours in 0.5× TBE and exposed 
using a PhosphorImager.
Enrichment analyses. To assess functional and disease-related 
association of RBM20 splice substrates, enrichment analysis was per-
formed with EGAN (42). To estimate the nature of transcript-process-
ing events leading to differential usage of Rbm20-regulated exons, 
overlapping transcript events as annotated by Ensembl were assigned 
to exonic regions. The significant enrichments of GO terms and MeSH 
and those for certain event types of exons in direct Rbm20 targets 
when compared with all exons expressed in the heart were evalu-
ated with the hypergeometric test, and significant enrichments were 
adjusted for multiple testing using Bonferroni’s method.
Construction of RNA maps. We determined the coverage profiles of 
HITS-CLIP reads for all differential used exons as defined above. We 
split the exons into activated (ΔPSI > 0.01) or repressed (ΔPSI < –0.01) 
exons and compared the coverage profiles of both sets with the read cov-
erage of control sets of the same size that were randomly sampled from 
nondifferential exons. We only counted the start positions of reads, and 
duplicated identical reads were only counted once. We investigated 
regions from 400 bp upstream of the 3′ splice site to 50 bp into the exon 
and from 50 bp upstream of the 5′ splice site to 400 bp into the down-
stream intron of differentially used exons and their adjacent neighbors. 
We smoothed the coverage profiles using the ggplot2 R package, which 
applies a generalized additive model with integrated smoothness esti-
mation and plots the smoothed coverage along with its 95% CI.
Splice reporter assay. We quantified RBM20 activity in a dual lucifer-
ase splice reporter assay (5) using a mini-gene representing titin PEVK 
exons 4 through 13 and a RNA destabilization motif for increased signal 
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